

Dorothy Beckett
Christina Liu
Alvin Yeh

*Division of Biophysics,
Biomedical Technology, and
Computational Biosciences
(BBCB), NIGMS*

Miljan Simonovic

*Division of Pharmacology,
Physiology, and Biological
Chemistry (PPBC), NIGMS*

NIGMS Biomedical Technology Optimization & Dissemination (BTOD) Centers Program

Contact: NIGMS_BTODMailbox@nigms.nih.gov



Dorothy Beckett



Christina Liu



Alvin Yeh



Miljan Simonovic

- **Today's Webinar:**

- **What are the goals of BTOD Center Program?**
- **What is the structural framework for achieving these goals?**
- **How are the goals and structure implemented in TWO active BTOD Centers?**


- **Send questions about application preparation to:
NIGMS_BTODMailbox@nigms.nih.gov**

OUTLINE

- **BTOD Program Overview**
- **Descriptions of two active BTOD Centers by the Principal Investigators**
- **Q&A with PIs and NIGMS Staff**
- **Please type any questions related to the webinar in the Chatbox**

NIGMS Biomedical Technology Development Pipeline

Untested Concept to Broad Utility



BTOD Program Goals

Optimize

state-of-the-art, late-stage technologies to enable broad use

Disseminate

the technologies for use by expert and non-expert biomedical researchers



Three-component Framework for Achieving BTOD Center Program Goals

**Technology
Optimization
Projects
(TOPs)**

**Driving
Biomedical
Projects
(DBPs)**

**Community
Engagement
(CE)**



Technology Optimization Projects (TOPs)

- **Leading-edge, late-stage technologies that are in NIGMS mission**
- **Variations of a single technology or multiple technologies that support a single goal**
- **Potential for broad adoption by expert and non-expert biomedical researchers**



DBPs

Driving Biomedical Projects (DBPs)


TOPs

- **Independently funded research projects**
- **Challenge the Center technology to drive optimization**
- **Provide a range of scientific test-beds for the Center technology**
- **Drawn from diverse, nationally distributed research labs**

Community Engagement (CE)

- **Develop self-sustaining activities to disseminate technologies**
- **Host a user-friendly website**
- **Provide training for diverse research communities**
- **Engage in technology commercialization**

BTOD Centers Integrate the Three Components



Features of BTOD Center Technologies

- Current state-of-the-art or unique technologies with demonstrated utility
- Technologies require optimization to make them broadly useful to the biomedical research community
- Potential utility for a variety of biomedical research problems
- In NIGMS mission



NIGMS Mission

The National Institute of General Medical Sciences (**NIGMS**) supports basic research that increases **understanding of fundamental biological processes** and lays the **foundation** for future advances in disease diagnosis, treatment, and prevention.

NIGMS also supports research in specific clinical areas that affect multiple organ systems, e.g., sepsis and anesthesiology

- NIGMS-funded scientists investigate how living systems work at a range of levels, from molecules and cells to tissues and organs, in research organisms, humans, and populations.
- NIGMS supports **research and technology development** aimed at understanding general principles, mechanisms, and processes.

Potential Technology Areas for BTOD Centers

- Bioanalytical Chemistry & Tools
- Chemical and Synthetic Biology
- Computational Tools for Biostatistics and Bioinformatics
- High-throughput Biochemistry
- Imaging Tools & Methods
- Microfluidics-based Tools for Biotechnology
- Single Cell Technologies
- Technologies for Structural Biology
- Multi-scale Computational Modeling of Biological Systems
- Spectroscopy and Spectrometry Tools for Interrogating Biological Systems

Current BTOD Centers

- **Center on Macromolecular Dynamics by NMR Spectroscopy (COMD/NMR)**
New York Structural Biology Center
- **Center on Probes for Molecular Mechanotechnology (CPMM)**
Emory University
- **National Resource for Advanced NMR Technology**
Florida State University and the University of Florida
- **Native Mass Spectrometry Guided Structural Biology Center (nMS→ SB)**
Ohio State University
- **The GCE4All Center: Unleashing the Potential of Genetic Code Expansion for Biomedical Research**
Oregon State University
- **UTSW-UNC Center for Cell Signaling Analysis**
UT Southwestern Medical Center and the University of North Carolina Chapel Hill

Two BTOD Centers presented by the Principal Investigators

- **The GCE4All Center: Unleashing the Potential of Genetic Code Expansion for Biomedical Research**

- Oregon State University, Dr. Ryan Mehl, Principal Investigator




- **Native Mass Spectrometry Guided Structural Biology Center (nMS→ SB)**

- Ohio State University, Dr. Vickie Wysocki, Principal Investigator



Ryan Mehl
GCE4All Research Center
Dept. of Biochemistry & Biophysics
Oregon State University



National Institute
of General Medical
Sciences





Oregon State
University

(RM1-GM144227)

GCE4All Center Structure

We aim to optimize and disseminate GCE technology such that it becomes a basic tool for protein research that is accessible **by all**




What is Genetic Code Expansion Technology?

The ability to site-specifically encode new amino acid chemistry on a protein.

First in cell demonstration 2021.

More than 300 amino acids have been encoded.

Most model organisms have been expanded.



No major equipment or software

Chemical synthesis of amino acids


Directed evolution of translation

Optimization of evolved translation for needed organism


Optimization of protein scale

Optimization of amino acid functionality for intended use


Dissemination of optimized methods and increase access to required optimized reagents



GCE technology




This is chemistry that must be optimized in live cells



What GCE to optimize?

What are NIH funded researchers needing?

TOP Cores



We selected amino acids that would have the greatest immediate impact for currently funded NIH researchers



9 Driving Biomedical Projects (DBPs)

Investigator	Project
E. Gouaux (OHSU)	Direct On-grid Capture of Protein Complexes for CryoEM
C. Ahern (U of Iowa)	Functional Consequences of Disease Mutation in Membrane Proteins
S. Gordon & B. Zagotta (U of Wash)	Conformational Dynamics & Regulation of Ion Channels
M. Waters (UNC)	Engineering of Novel Histone eWriter Proteins & Studying Pi-Pi Interactions
Edwin Antony (SLU)	Deciphering the Assembly of Multi-Protein Complexes in DNA Metabolism
E.J. Petersson (UPenn)	Probing Protein Misfolding in Neurodegeneration
A. Gronenborn (U of Pitt)	Development of Efficient Eukaryotic In Cell ^{19}F NMR
J. Prescher (UC Irvine)	Genetically encodable cyclopropenones for bioorthogonal crosslinking
H. Arthanari (Harvard)	The use of GCE technologies to study the interaction of disordered section of the kinase Wee-1 with its structured domain

What GCE to optimize? (2)

What are NIH funded researchers needing?

TOP Cores





9 Driving Biomedical Projects (DBPs)

22

Investigator	Project
E. Gouaux (OHSU)	Direct On-grid Capture of Protein Complexes for CryoEM
C. Ahern (U of Iowa)	Functional Consequences of Disease Mutation in Membrane Proteins
S. Gordon & B. Zagotta (U of Wash)	Conformational Dynamics & Regulation of Ion Channels
M. Waters (UNC)	Engineering of Novel Histone eWriter Proteins & Studying Pi-Pi Interactions
Edwin Antony (SLU)	Deciphering the Assembly of Multi-Protein Complexes in DNA Metabolism
E.J. Petersson (UPenn)	Probing Protein Misfolding in Neurodegeneration
A. Gronenborn (U of Pitt)	Development of Efficient Eukaryotic In Cell ^{19}F NMR
J. Prescher (UC Irvine)	Genetically encodable cyclopropenones for bioorthogonal crosslinking
H. Arthanari (Harvard)	The use of GCE technologies to study the interaction of disordered section of the kinase Wee-1 with its structured domain

What GCE to optimize? (3)

What are NIH funded researchers needing?



ACD



J. Petersson
UPenn

*Dual in E. coli
encoding of
ACD with a
good
bioorthogonal
ligation*



B. Zagotta





S. Gordon

Univ. of Washington

*ACD encoding
in mammalian
cells to resolve
conformational
distributions*

What GCE to optimize? (4)

What are NIH funded researchers needing?



ACD



B. Zagotta



S. Gordon

Univ. of Washington

ACD encoding in mammalian cells to resolve conformational distributions

Before GCE4All: fluorescence resonance energy transfer (FRET) approaches using a fluorescent noncanonical amino acid donor (Anap).

Acid's high quantum yield (**2.5x**) and photostability (**10x**). First eukaryotic FLIM studies with GCE because of its 15–16 ns fluoresce lifetime in water (**2-3x** that of fluorophores in use).


Jones et al. Chem. Sci., 2021, 12, 11955

We demonstrated that the long, single-exponential fluorescence lifetime of Acid is suitable for time-resolved measurements of the tmFRET efficiency allowing us to resolve conformational distributions of proteins in cells.




Zagotta et al. eLife 2021;10:e70236

What GCE to optimize? (5)

What are NIH funded researchers needing?




Measuring conformational changes by DEER spectroscopy in live mammalian cells is limited because EPR probes are reduced in cells.



Rapid Labeling In Live Eukaryotic cells



S. Stoll



B. Zagotta



S. Gordon




A. Rajca

Univ. of Washington


Univ. of Nebraska

What GCE to optimize? (6)

What are NIH funded researchers needing?



S. Stoll



B. Zagotta



S. Gordon



A. Rajca

Univ. of Washington

Univ. of Nebraska



Site-specific
Labeling rate k_2 ($M^{-1}s^{-1}$)

Cysteine	SCO-Lysine	Tet-v4.0Ph
Gold standard	Previous work	Present work
<i>In vitro</i>	<i>In vitro</i>	<i>In-cell</i>
No	Yes	Yes
10^5 (fast)	400 ± 200 (slow)	$4.0 \times 10^5 \pm 10^4$ (fast)
Short	Long and more flexible	Short and less flexible

Improve label rate **1000x**

What GCE to optimize? (7)

What are NIH funded researchers needing?




26

Improve label lifetime **15x**



S. Stoll



B. Zagotta




S. Gordon



A. Rajca

Univ. of Washington

Univ. of Nebraska




	Cysteine Gold standard	SCO-Lysine Previous work	Tet-v4.0Ph Present work
Site-specific	No	Yes	Yes
Labeling rate k_2 ($M^{-1}s^{-1}$)	10^5 (fast) Short	400 ± 200 (slow) Long and more flexible	$4.0 \times 10^5 \pm 10^4$ (fast) Short and less flexible




Improve label rate **1000x**

What GCE to optimize? (8)

What are NIH funded researchers needing?



Measuring conformational changes by DEER spectroscopy in live mammalian cells is limited because EPR probes are reduced in cells.




Rapid Labeling In Live Eukaryotic cells

Jana et al. J. Am. Chem. Soc. 2023, 145, 27, 14608–14620



S. Stoll



B. Zagotta



S. Gordon


University of Washington



A. Rajca

University of Nebraska

What GCE to optimize? (9)



What are NIH funded researchers needing (now)?

How to have the maximum impact with the fewest research areas?

Who drives the publication to completion?

How to cycle DBPs out and new DBPs in?

When is the optimized technology ready for broad distribution?

Community Engagement - (CE)

Website

One-stop GCE resource that supports Center administrative activities, provides up-to-date information about Center activities, and provides links to instructional/dissemination materials



gce4all.oregonstate.edu

GCE knowledgebase

One-stop resource for all things GCE
planned for 2023

Training & Support

GCEbb listserve

A community forum for help troubleshooting experiments and other networking

International GCE webinar

3rd Thursdays Oct-Jun

Workshops

2-4 each year hands-on support for applications using specific “certified” GCE tools

Online training modules

Available 24/7 worldwide

Dissemination


“Certified” Protocols & Materials



Publications & Presentations

GCE Conferences

August 8-11th, 2024 Oregon State University
Chairs: Kathrin Lang & Abhishek Chatterjee



NIH Biomedical Technology Optimization and Dissemination Center

Native Mass Spectrometry Guided Structural Biology


nativems.osu.edu



NIH Biomedical Technology Optimization and Dissemination Center

Native Mass Spectrometry Guided Structural Biology



nativems.osu.edu



DBPs for RM1: geographical and structural diversity

Baker (WA)

De Novo interleukin mimics for immunotherapy




Sayed (U24)

Tau aggregates from Alzheimer's
(TX, OH, WA, CA)

Kelly (CA)


Amyloid disease



Ollman Sapphire (CA)



Glycoproteins

Laganowsky (TX, NC, AZ)
Membrane protein lipid interactions



Cover and Ohi (MI, TN)



Type IV Protein Secretion



Torbett, Sarafianos (U54) Dynamics of HIV core interactions
(NC, WA, etc)

Disney (FL)

RIBOTACs



Woodson (MD)

RNA-protein complexes for genetic control

Gupta (CT)


Membrane proteins in lipid vesicles



NIH Biomedical Technology Optimization and Dissemination Center

Native Mass Spectrometry Guided Structural Biology


nativems.osu.edu




Goal: optimize user-compatible native MS technology to characterize the assembly and disassembly of macromolecular protein complexes

Goal: optimize user-compatible native MS technology to characterize the assembly and disassembly of macromolecular protein complexes


TOP1 Front End/ Solution Phase




TOP2 Ion Selection/ Separation/Manipulation




TOP3 Ion Stability/ Computations



TOP1, Front End: 1D and 2D Online buffer exchange



TOP1, Front End: 1D and 2D Online buffer exchange




Driving Biomedical Projects


Baker



Disney, Scripps



TOP1, Front End: 1D and 2D Online buffer exchange




Driving Biomedical Projects

Baker



Disney, Scripps




Why late stage? first column now commercial
adoption occurring in multiple labs

Thermo Scientific™
NativePac OBE-1™



https://connect.acspubs.org/CENWebinar_Thermo_3_23_22




TOP1, Front End: Variable temperature ESI (vT-ESI)




Dissecting the Thermodynamics of ATP Binding to GroEL One Nucleotide at a Time
T. E. Walker et al. ACS Cent Sci 2023, 9, 466-475.

TOP1, Front End: Variable temperature ESI (vT-ESI)


Driving Biomedical Projects



Kelly (CA)
Amyloid disease





Laganowsky (TX, NC, AZ)
Membrane protein lipid interactions




Dissecting the Thermodynamics of ATP Binding to GroEL One Nucleotide at a Time
T. E. Walker et al. ACS Cent Sci 2023, 9, 466-475.

TOP1, Front End: Variable temperature ESI (vT-ESI)


Driving Biomedical Projects



Kelly (CA)
Amyloid disease



Laganowsky (TX, NC, AZ)
Membrane protein lipid interactions





Why late stage? adoption in multiple labs
pharma collaborations
multi-vendor adoption possible

Dissecting the Thermodynamics of ATP Binding to GroEL One Nucleotide at a Time
T. E. Walker et al. ACS Cent Sci 2023, 9, 466-475.

TOP2, Ion Selection: Digital Quadrupole

Orbitrap Exactive Plus EMR




Optimization of a Digital Mass Filter for the Isolation of Intact Proteins in Stability Zone 1,1

R. L. Schrader et al. *Anal. Chem.* 2023, 95, 3062.

TOP2, Ion Selection: Digital Quadrupole


Orbitrap Exactive Plus EMR



Why late stage?

Illustrated at TAMU & OSU





Illustrated in multiple vendors' MS



Optimization of a Digital Mass Filter for the Isolation of Intact Proteins in Stability Zone 1,1

R. L. Schrader et al. *Anal. Chem.* 2023, 95, 3062.

TOP2, Electron Capture Charge Reduction-Surface Induced Dissociation





Driving Biomedical Projects

La Jolla
Institute
FOR IMMUNOLOGY


Ollman Sapphire (CA)
Glycoproteins

Unpublished


TOP3, Protein Stability: Collision induced unfolding



Driving Biomedical Projects





Woodson (MD)
RNA-protein
complexes for
genetic control




Cover and Ohi (MI, TN)
Type IV Protein Secretion


TOP3, Protein Stability: Collision induced unfolding



Driving Biomedical Projects





Woodson (MD)
RNA-protein
complexes for
genetic control



Cover and Ohi (MI, TN)
Type IV Protein Secretion



Why late stage? CIU option across dozens of labs worldwide
many pharma collaborations
multi-vendor adoption in progress

TOP2&3, Computations: Integrative Modeling for Quaternary Structure





protein tertiary and quaternary structure prediction

Combine MS and/or ion mobility data with complementary low resolution structural data for integrative modeling









protein quaternary structure prediction



protein tertiary structure prediction

TOP2&3, Computations: Integrative Modeling for Quaternary Structure






Combine MS and/or ion mobility data with complementary low resolution structural data for integrative modeling

Why late stage?

tools are beta tested and provided as developed, extended, and improved (Rosetta or OpenFold)

Technology Partnership Projects



Community Engagement (CE)

Website

nativems.osu.edu

Overview
Details & News
Protocols
Contact link

Training & Support

Short Courses

Workshops

Webinars

**Onsite and partner site
technique training**

**Collaborator training:
technique choice and
data interpretation**

Dissemination

Vendor Products
Prototypes to labs
Software

**Publications &
Presentations**

Graduate Placements
Industrial Advisory Board

**Move technology
into core facilities**

Question & Answer Session with PIs and NIGMS Staff



Please type your questions in the Chatbox.

Questions after the webinar? Send to

NIGMS_BTODMailbox@nigms.nih.gov

Application Submission

- [PAR-23-110](#): Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1-Clinical Trial Not Allowed)
- May/January receipt dates with next receipt date of January 26, 2024
- Send questions about application preparation to:
[**NIGMS BTODMailbox@nigms.nih.gov**](mailto:NIGMS_BTODMailbox@nigms.nih.gov)

For more information: NIGMS BTOD Website

- General descriptions of the BTOD Program and funded Centers
- FAQs



<https://www.nigms.nih.gov/about/overview/BBCB/biomedicaltechnology/Pages/btdd.aspx>